NCT04447911View on ClinicalTrials.gov

Effects of the SGLT2 Inhibitor Empagliflozin in Patients With Euvolemic and Hypervolemic Hyponatremia

PHASE4RecruitingINTERVENTIONAL
Enrollment

172

Participants

Timeline

Start Date

February 4, 2021

Primary Completion Date

January 31, 2026

Study Completion Date

February 28, 2026

Conditions
HyponatremiaSIADHLiver FailureKidney Failure
Interventions
DRUG

Empagliflozin 25 MG

Empagliflozin 25mg per os once daily for 30 days

DRUG

Placebo

Placebo per os once daily for 30 days

Trial Locations (3)

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne

4031

RECRUITING

University Hospital Basel, Basel

6000

RECRUITING

Kantonsspital Luzern, Lucerne

All Listed Sponsors
collaborator

Luzerner Kantonsspital

OTHER

collaborator

Centre Hospitalier Universitaire Vaudois

OTHER

lead

University Hospital, Basel, Switzerland

OTHER